Cengild Medical Berhad, an investment holding company, (0243) Fair Value & Analysis
Healthcare · MY · Market cap 158M MYR
Fair value as of: Jul 16, 2026
From 16 valuation models · updated 26 days ago
Share price +2.6% over the past month.
A solid business, screening 23% undervalued on our models.
What matters now
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (0.1700 MYR to 0.3100 MYR) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
52‑month range 0.1900 MYR – 0.5179 MYR · fair‑value band 0.1700 MYR – 0.3100 MYR · the 0.1950 MYR price screens below the 0.2400 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Cengild Medical Berhad, an investment holding company, (0243) currently trades at 0.1950 MYR, while our model-based Fair Value estimate is 0.2400 MYR, implying the stock looks roughly 23.1% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Cengild Medical Berhad, an investment holding company, generated revenue of 73.2M MYR at a net margin of 12.9%. Revenue declined 9.7% year over year. It earns a return on equity of 9.0%. Net debt stands at 31.0M MYR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 0.1700 MYR (bear case) to 0.3100 MYR (bull case); at 0.1950 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 23%, 0243 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (0.2400 MYR) versus Economic Profit (0.0700 MYR). Highest evidence: Residual Income (76).
Notify me when 0243 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general …
Full company description
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cengild Medical Berhad, an investment holding company, reported revenue of 80.0M MYR in FY2025 versus 63.5M MYR in FY2021, a compound +6.0%/yr. Reported net income was 11.1M MYR in FY2025, compounding +2.5%/yr from FY2021.
Watch 0243: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Cengild Medical Berhad, an investment holding company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cengild Medical Berhad, an investment holding company, (0243) overvalued or undervalued?
What is the fair value of 0243?
What is the quality score of 0243?
What is the revenue of Cengild Medical Berhad, an investment holding company, (0243)?
What is the net profit margin of 0243?
Does Cengild Medical Berhad, an investment holding company, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cengild Medical Berhad, an investment holding company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.